Accellacare offers experience in phase II-IV obesity studies involving most major drug classes including: GLP-1 receptor agonist, SGLT-2 inhibitors, DP-4 Inhibitors, Insulin and Insulin Analogs, and Alpha Glucosidase Inhibitors just to name a few. Learn more about our experience: https://ow.ly/BXOO50SIZS1
Accellacare’s Post
More Relevant Posts
-
Development of the Synthetic Routes to PF-06878031, both scaled up at multiple facilities to generate >1.5MT in high purity Part 1: Selective Alkylation Route Part 2: Amide Reduction Route PF-06878031 is a key structural fragment of a range of oral late-stage glucagon-like peptide-1 receptor agonists (GLP-1-RA) under development for the indications of type-2 diabetes mellitus (T2DM) and weight loss https://lnkd.in/g4p5kGRs https://lnkd.in/g9NfSE3h
To view or add a comment, sign in
-
-
NASH is a clearly frustrating diagnosis with not much to offer to the patients except weight loss and GLP-1 agonists or insulin sensitizers. Beta- Receptor agonists are 93:1 concentrated in liver: Serum. Non selective thyroid hormones are cardiotoxic. MGL-3196,Resmitirom small molecule oral drug dosed 50-100mg are BetaSelective receptor agonists (20x more selective)that target liver cells and shown improvement in F1B-F3 Stages of NASH in recent phase3 trials. I think this is a great break through in the treatment drug panel of NASH.
To view or add a comment, sign in
-
Search & Evaluation | Strategic Partnerships | Cross-functional Team Leadership | Program & Alliance Management | Metabolic Diseases
Regeneron will be testing a range of doses and combos of semaglutide, trevogrumab (GFD8/myostatin mAb) and garetosmab (activin A mAb) in a Phase II study with the hope to counteract the significant muscle mass loss that accompanies GLP treatment and improve the quality of weight loss. https://lnkd.in/ewGDsBwu
To view or add a comment, sign in
-
In a shifting landscape, it can be difficult to pinpoint the greatest opportunities in obesity drug and device research and development. Explore the roles of multi-indicational efficacy and research, GLP-1 receptor agonists, and other trends and opportunities in the Q&A. https://ow.ly/pJ6Z50QU0ma
To view or add a comment, sign in
-
-
In a shifting landscape, it can be difficult to pinpoint the greatest opportunities in obesity drug and device research and development. Explore the roles of multi-indicational efficacy and research, GLP-1 receptor agonists, and other trends and opportunities in the Q&A. https://ow.ly/pJ6Z50QU0ma
To view or add a comment, sign in
-
-
Up front & free to read in our May issue #editorspicks: Phenotype-based targeted treatment of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes tinyurl.com/bp89t8aa
To view or add a comment, sign in
-
-
A phase 2 study has been initiated to evaluate the combination of bremelanotide and a PDE5 inhibitor in patients with erectile dysfunction who did not respond to prior PDE5 inhibitor monotherapy. https://lnkd.in/eHES5Vtm
Phase 2 study launches of bremelanotide plus a PDE5 inhibitor for erectile dysfunction
urologytimes.com
To view or add a comment, sign in
-
Diabetologist Consultant | Deputy Director, Alahsa Diabetes Center | Innovator in Insulin Pump Therapy & Diabetes Technology | Educator & Research Advocate
# Different medications associated with inducing of hyperglycemia The main mechanisms of medication-induced hyperglycemic based on medication class. Abbreviations: GC glucocorticoids, AP antipsychotics, BB beta blockers, PI protease inhibitor, mTORi mammalian target of rapamycin inhibitors, TKI tyrosine kinase inhibitor, PI3K phosphoinositide 3-kinase, AKT protein kinase B, CNI calcineurin inhibitors, SSA somatostatin analogue, ADT androgen deprivation therapy, IFN-A interferon alpha. Full article: https://lnkd.in/dgEGS8-M
To view or add a comment, sign in
-
-
AstraZeneca announced Phase I trial data for its PCSK9 inhibitor, AZD0708. AZD0780 is an oral small molecule PCSK9 inhibitor as a first-in-class therapy for patients with dyslipidemia that cannot be controlled by statins alone. PSCK9 is a well-known and validated target in lipid metabolism and inhibiting PSCK9 signalling has shown to be effective in reducing LDL cholesterol levels in plasma. Lower LDL-C levels are associated with a reduction in the risk of long-term cardiovascular disease and major cardiovascular events. Chemenu has been working to develop more compounds for drug discovery. Here come the building blocks we can provide: https://lnkd.in/geNFVmuf #AZD0708 #PCSK9 #Dyslipidemia #LDL-C #Chemenu #buildingblocks
To view or add a comment, sign in
-
-
In a shifting landscape, it can be difficult to pinpoint the greatest opportunities in obesity drug and device research and development. Explore the roles of multi-indicational efficacy and research, GLP-1 receptor agonists, and other trends and opportunities in the Q&A. https://ow.ly/pJ6Z50QU0ma
To view or add a comment, sign in
-